MRZ
0.275
570.7%
AR1
0.047
-70.6%
BUY
0.003
50%
MAY
0.007
-53.3%
VBC
0.15
30.4%
DTI
0.021
-30%
CR9
0.005
25%
VAR
0.005
-28.6%
LEG
0.01
25%
FRX
0.018
-28%
RKB
0.005
25%
MSG
0.008
-27.3%
TYX
0.005
25%
AYM
0.003
-25%
CPN
0.12
23.7%
NAE
0.003
-25%
SRR
0.049
22.5%
RDS
0.003
-25%
AN1
0.006
20%
T3D
0.075
-25%
MML
0.024
20%
ANG
0.215
-23.2%
GR8
0.23
17.9%
FAU
0.007
-22.2%
IMI
0.014
16.7%
SCN
0.021
-22.2%
MPR
0.007
16.7%
XPN
0.014
-22.2%
NHE
0.035
16.7%
TRI
0.022
-21.4%
BDG
0.058
16%
GLA
0.015
-21.1%
JGH
0.03
15.4%
AUR
0.023
-20.7%
AEV
0.008
14.3%
ALY
0.008
-20%
VBS
0.165
13.8%
CAV
0.004
-20%
SPQ
0.009
12.5%
FIN
0.008
-20%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CMH Clinical trial openfor enrollment

Chimeric Therapeutics (ASX:CHM), Australian leader in cell therapy, announces the Phase 18 ADVENT-AML clinical trial for patients with newly diagnosed Acute Myeloid Leukaemia is now open to enrolment at The University of Texas MD Anderson Cancer Center https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02762504-2A1499759